EP2295035
Tvívirkar lyfjasamsetningar sem byggjast á yfirformgerðum af angíótensín viðtakamótverkanda/tálma (ARB) og hlutlausum innrænum peptíðasa (NEP) hemli
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
4.11.2008EP published:
18.5.2016EP application number:
10173506.6
EP translation filed:
27.6.2016Grant published:
15.7.2016EPO information:
European Patent Register
Max expiry date:
3.11.2028Expiry date:
3.11.2017
Title:
Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
Timeline
Today
4.11.2008EP application
18.5.2016EP Publication
27.6.2016Translation submitted
15.7.2016Registration published
3.11.2017Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Inventor
Name:
Al-Fayoumi, SulimanAddress:
Morristown, NJ, US
Name:
Hu, JiahuiAddress:
Bridgewater, NJ, US
Name:
Kumaraperumal, NatrajanAddress:
Wayne, NJ, US
Name:
Royce, Alan EdwardAddress:
Saylorsburg, PA, US
Name:
Ruegger, ColleenAddress:
Morris Plains, NJ, US
Name:
Zannou, Erika AinaAddress:
Edison, NJ, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
985668 PDate:
6.11.2007Country:
US
Classification
Categories:
A61K 9/00, A61K 31/216, A61K 9/20, A61K 31/41
Annual fees
Number
Paid
Expires
Payer
Number: 9
Paid: 14.9.2016
Expires: 3.11.2017
Payer: Árnason Faktor